This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.
early-stage NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC).
Tecentriq was the first approved cancer immunotherapy for the first-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with chemotherapy.
Imfinzi is already used to treat unresectable, stage 3 non-small cell lung cancer (NSCLC) and extensive-stage small cell lung cancer (ES-SCLC) as well as advanced bladder cancer. ... The company has a broad development programme for Imfinzi plus
AstraZeneca has announced that its PD-L1 inhibitor Imfinzi (durvalumab) showed a ‘sustained and clinically meaningful’ survival benefit for patients with extensive stage cell lung cancer (ES-SCLC). ... For treatment purpose, clinicians divide SCLC
More Imfinzi data will be presented at the European Society for Medical Oncology (ESMO) Congress, showing three-year overall survival data in extensive-stage small cell lung cancer (ES-SCLC), the
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the ... SCLC is less common than NSCLC but tends to be more aggressive,
More from news
Approximately 6 fully matching, plus 42 partially matching documents found.
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer.
Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
No results were found
Bedrock Healthcare Communications is an award-winning, independent agency founded in 2011. We partner with healthcare professionals, patients, and global pharmaceutical...